Duke-Margolis’ Gregory W. Daniel Named New Editor-In-Chief of DIA’s Therapeutic Innovation & Regulatory Science
Daniel joined the Duke-Margolis Center for Health Policy in January 2016 and leads the Center's pharmaceutical and medical device policy portfolio, which includes policy and data strategies for improving development and access to innovative pharmaceutical and medical device technologies. His expertise spans post-market evidence development to support increased value; improving regulatory science and drug development tools; optimizing biomedical innovation, and drug and device value-based payment reforms.
Daniel is also a Senior Advisor to the Reagan-Udall Foundation for the FDA and Adjunct Associate Professor in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy. He is also a Visiting Expert for the Duke-NUS Centre of Regulatory Excellence at the Duke-National University of Singapore Medical School. Previously, he was Managing Director for Evidence Development & Biomedical Innovation at the Center for Health Policy at the Brookings Institution, and Vice President, Government and Academic Research at HealthCore (a subsidiary of Anthem, Inc).
“We have seen significant advances in science and medicine translate into viable transformative therapies for patients over the last decade. This journal is very well positioned to be the home for researchers working to understand how these advances, coupled with new regulatory tools and innovative payment approaches, will affect patient care, access, and outcomes,” said Daniel. “I look forward to leading this journal into its next phase of growth as it continues to provide the policy and research community that compromise the DIA membership with the rigorous studies and expert commentary necessary to advance knowledge.”
“We are delighted to welcome Dr. Gregory Daniel as the next editor-in-chief of TIRS. Dr. Daniel brings scientific expertise in a wide range of topic areas, including pharmacoeconomics, pharmacoepidemiology, and regulatory science as well as extensive editorial and publishing experience with TIRS.” said Barbara Lopez Kunz, Global Chief Executive, DIA. “A distinguished leader and preeminent researcher, Dr. Daniel is perfectly poised to ensure that the journal continues to develop and reaches new heights in the years ahead.”